

## **Supplement**

**Supplementary Table 1. EPA and DHA levels in human subjects.**

**Supplementary Figure 1. GC-MS spectrum of methyl-d<sub>5</sub>-EPA, methyl-d<sub>5</sub>-DHA and methyl parinarate.**

**Supplementary Figure 2. Peritoneal leukocyte composition: FACS analysis.** Lavage cells were stained with PE-conjugated anti-mouse Ly-6G and PerCP-Cy5.5-conjugated anti-mouse CD11b. Ly-6G is primarily expressed on PMN while CD11b is expressed on both PMN and monocytes.

A) zymosan A-induced acute inflammation; B) acute inflammation + d<sub>5</sub>-EPA and d<sub>5</sub>-DHA.

**Supplementary Figure 3. Neutrophil migration on P-selectin surface without IL-8.**




Significant chemotaxis was not observed with neutrophils on tethered P-selectin surface in the absence of IL-8. At a few minutes after establishing a chemoattractant IL-8 gradient, neutrophils display sustained migration in the direction of the gradient. Results represent the mean  $\pm$  SEM, n=12, for each.

**Supplementary Video: RvD1 “stops” neutrophil migration in an IL-8 chemotactic gradient.**


**Table.1 EPA and DHA levels in Human Subjects**

Reference	Subjects	EPA and DHA levels	Note
Gong et al., (1992) <sup>21</sup>	Control group (n=91)	EPA 0.49 ± 0.04 (%) DHA 1.34 ± 0.06 (%)	% of Plasma fatty acids
Newcomer et al., (2001) <sup>22</sup>	Control group (n=156, Men)	EPA 0.61 ± 0.36 (%) DHA 4.17 ± 1.26 (%)	% of Total fatty acids in RBC
Albert et al., (2002) <sup>23</sup>	Control group (n=184)	EPA 1.84 ± 0.53 (%) DHA 2.38 ± 0.78 (%)	% of Total fatty acids in blood
Kew et al., (2004) <sup>24</sup>	Placebo control, Baseline (n=8-12)	EPA 0.7 ± 0.3 (%) DHA 2.8 ± 1.2(%)	% of Total fatty acids in neutrophils
Wakai et al., (2005) <sup>25</sup>	Healthy subjects (n=1257:Japanese, Women: 626, Men: 631)	Women EPA 2.47(%) DHA 4.93(%)  Men EPA 2.82(%) DHA 5.07(%)	% of Total fatty acids in serum


Recently reviewed by Fritsche (2007, Ref <sup>62</sup>) in detail.



Suppl Fig.1



**Supplemental Figure.2**



**Suppl Fig.3**